Business
Amazon com : AWS Announces General Availability of AWS HealthOmics in the Asia Pacific (Tokyo) Region
Amazon com : AWS Announces General Availability of AWS HealthOmics in the Asia Pacific (Tokyo)
About this update from Amazon.com, Inc.
Key Takeaways: AWS HealthOmics, a HIPAA-eligible and ISMAP-compliant service that accelerates clinical diagnostic testing and drug discovery through fully managed bioinformatics workflows, is now generally available in the AWS Asia Pacific (Tokyo) Region Customers can run scalable genomic analysis pipelines in Japan while leveraging AWS AI services for data interpretation and drug discovery Eisai has begun validating AWS HealthOmics, with expectations for faster genomic analysis and more efficient management of complex workflows Amazon Web Services (AWS), an Amazon.com, Inc. company, today announced the general availability of AWS HealthOmics in the AWS Asia Pacific (Tokyo) Region. AWS HealthOmics is a HIPAA-eligible and Japan's Information System Security Management and Assessment Program (ISMAP)-compliant service that helps accelerate clinical diagnostic testing and drug discovery through fully managed bioinformatics workflows. With availability in Tokyo Region, researchers and healthcare organizations can now execute scalable bioinformatics pipeline with built-in security and compliance -without provisioning or managing underlying infrastructure. Each year, approximately 1 million people in Japan are newly diagnosed with cancer-the country's leading cause of death since 1981. Another 1 million patients live with 348 government-designated intractable diseases, many lacking effective treatments. Genomic medicine-analyzing a patient's complete genetic information to identify disease-causing variants-offers a path toward overcoming these challenges. The Japanese government enacted the Genomic Medicine Promotion Act in 2023, is advancing utilization of 600,000 samples held by Biobank Network Japan, and in March 2026 established the Japan Genomic Medicine Promotion Organization to collect and analyze whole genome data from 7,000 patients annually, scaling to more than 100,000. While conventional gene panel testing covers approximately 1.5% of the genome in Japan, whole genome sequencing analyzes the remaining regions-generating exponentially larger datasets. Organizations urgently need infrastructure that combines secure workflow execution with high-speed analysis, freeing researchers to focus on science rather than infrastructure management. Accelerating Genomic Research with AWS AI Services AWS HealthOmics lets researchers focus on discovery instead of man...